Maggio 8, 2026

News Nazionali

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

(Adnkronos) - BRENTWOOD, Tenn., Oct. 18, 2023 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax") today announced top-line results from a Cardiovascular Health...